首页> 外文OA文献 >Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer
【2h】

Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer

机译:肿瘤抑制基因aImp3的表达缺失预示了肌肉浸润性膀胱癌中放疗后的存活率

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this study was to test the utility of AIMP3, an upstream regulator of DNA damage response following genotoxic stress, as a clinical biomarker in muscle-invasive bladder cancer (MIBC). AIMP3 was identified from a meta-analysis of a global gene-expression dataset. AIMP3 protein expression was determined by immunohistochemistry on a customised bladder cancer tissue-microarray (TMA). The mechanism of gene silencing was probed using methylation-specific PCR. The association between AIMP3 expression, Tp53 transactivity and genomic stability was analysed. In vitro AIMP3 translocation to the nucleus in response to ionising radiation was demonstrated using immunofluorescence. Radiosensitisation effects of siRNA-mediated AIMP3-knockdown were measured using colony forming assays. TMAs derived from patients enrolled in BCON, a Phase III multicentre radiotherapy trial in bladder cancer (ISRCTN45938399) were used to evaluate the association between AIMP3 expression and survival. The prognostic value of AIMP3 expression was determined in a TMA derived from patients treated by radical cystectomy. Loss of AIMP3 expression was frequent in MIBC and associated with impaired Tp53 transactivity and genomic instability. AIMP3-knockdown was associated with an increase in radioresistance. Loss of AIMP3 expression was associated with survival in MIBC patients following radiotherapy (HR=0.53; 95% CI: 0.36 to 0.78, p = 0.002) but was not prognostic in the cystectomy set. In conclusion, AIMP3 expression is lost in a subset of bladder cancers and is significantly predictive of survival following radiotherapy in MIBC patients. © 2014 UICC.
机译:这项研究的目的是测试AIMP3作为遗传毒性应激后DNA损伤反应的上游调节剂,作为肌肉浸润性膀胱癌(MIBC)的临床生物标志物的用途。 AIMP3是通过对全球基因表达数据集的荟萃分析确定的。 AIMP3蛋白表达是通过免疫组织化学在定制的膀胱癌组织微阵列(TMA)上确定的。使用甲基化特异性PCR探究了基因沉默的机制。分析了AIMP3表达,Tp53活性和基因组稳定性之间的关系。使用免疫荧光技术证实了体外AIMP3响应电离辐射而转移到细胞核。使用集落形成测定法测量siRNA介导的AIMP3敲低的放射增敏作用。来自BCON入组患者的TMA(一项在膀胱癌中进行的III期多中心放射治疗试验(ISRCTN45938399))用于评估AIMP3表达与生存之间的关联。在源自经根治性膀胱切除术治疗的患者的TMA中确定AIMP3表达的预后价值。 AIMP3表达的丧失在MIBC中很常见,并且与Tp53的转导能力受损和基因组不稳定有关。 AIMP3-nockdown与放射抗性的增加有关。 AIMP3表达的丧失与放疗后MIBC患者的存活率相关(HR = 0.53; 95%CI:0.36至0.78,p = 0.002),但在膀胱切除术组中无预后。总之,AIMP3表达在一部分膀胱癌中丢失,并显着预测了MIBC患者放疗后的存活率。 ©2014 UICC。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号